Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan B Corcoran

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2020
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in OncologyOzge Gumusay, Pietro Paolo Vitiello, Chiara Wabl, et al.
Cancer Research|November 1, 2008
Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous miceRyan B Corcoran, Tal Bachar Raveh, Monique T Barakat, et al.
Science Signaling|November 25, 2010
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutationRyan B Corcoran, Dora Dias-Santagata, Kristin Bergethon, et al.
Radiology. Imaging Cancer|March 29, 2021
Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with <i>BRAF</i> Mutation and 5-year Overall SurvivalAdrian A Negreros-Osuna, Anushri Parakh, Ryan B Corcoran, et al.
Cancer Cell|January 30, 2026
Emerging landscape of KRAS inhibitors in cancer treatmentJakob M Riedl, Hiroyuki Matsubara, Reid McNeil, et al.
Nature Communications|June 14, 2020
Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspotsPégah Jalili, Danae Bowen, Adam Langenbucher, et al.
Cancer Research|May 19, 2011
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesisRyan B Corcoran, Gianmarco Contino, Vikram Deshpande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2019
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS<sup>G12C</sup> InhibitionMeagan B Ryan, Ferran Fece de la Cruz, Sarah Phat, et al.
Cell Reports|June 22, 2022
KRAS<sup>G12C</sup>-independent feedback activation of wild-type RAS constrains KRAS<sup>G12C</sup> inhibitor efficacyMeagan B Ryan, Oluwadara Coker, Alexey Sorokin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2023
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered CholangiocarcinomaQibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2020
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in OncologyOzge Gumusay, Pietro Paolo Vitiello, Chiara Wabl, et al.
Cancer Research|November 1, 2008
Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous miceRyan B Corcoran, Tal Bachar Raveh, Monique T Barakat, et al.
Science Signaling|November 25, 2010
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutationRyan B Corcoran, Dora Dias-Santagata, Kristin Bergethon, et al.
Radiology. Imaging Cancer|March 29, 2021
Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with <i>BRAF</i> Mutation and 5-year Overall SurvivalAdrian A Negreros-Osuna, Anushri Parakh, Ryan B Corcoran, et al.
Cancer Cell|January 30, 2026
Emerging landscape of KRAS inhibitors in cancer treatmentJakob M Riedl, Hiroyuki Matsubara, Reid McNeil, et al.
Nature Communications|June 14, 2020
Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspotsPégah Jalili, Danae Bowen, Adam Langenbucher, et al.
Cancer Research|May 19, 2011
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesisRyan B Corcoran, Gianmarco Contino, Vikram Deshpande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2019
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS<sup>G12C</sup> InhibitionMeagan B Ryan, Ferran Fece de la Cruz, Sarah Phat, et al.
Cell Reports|June 22, 2022
KRAS<sup>G12C</sup>-independent feedback activation of wild-type RAS constrains KRAS<sup>G12C</sup> inhibitor efficacyMeagan B Ryan, Oluwadara Coker, Alexey Sorokin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2023
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered CholangiocarcinomaQibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Pageof 11